Related references
Note: Only part of the references are listed.RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Ryan M. Carr et al.
NATURE COMMUNICATIONS (2021)
A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
Nico Gagelmann et al.
BLOOD ADVANCES (2021)
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Anthony M. Hunter et al.
CLINICAL CANCER RESEARCH (2021)
Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients
Giacomo Coltro et al.
LEUKEMIA (2020)
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms
Emma C. DiFilippo et al.
LEUKEMIA (2020)
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
BLOOD (2020)
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
Prateek Pophali et al.
BLOOD CANCER JOURNAL (2020)
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas et al.
LEUKEMIA (2019)
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Tucker Coston et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Peter Valent et al.
HAEMATOLOGICA (2019)
Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia
Prateek A. Pophali et al.
BLOOD CANCER JOURNAL (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
Mrinal M. Patnaik et al.
HAEMATOLOGICA (2019)
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
V. Santini et al.
LEUKEMIA (2018)
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases
Mrinal M. Patnaik et al.
LEUKEMIA (2018)
FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous
Mrinal M. Patnaik et al.
LEUKEMIA & LYMPHOMA (2018)
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
Terra L. Lasho et al.
BLOOD CANCER JOURNAL (2018)
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
Mrinal M. Patnaik et al.
BLOOD CANCER JOURNAL (2018)
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
Matthieu Duchmann et al.
EBIOMEDICINE (2018)
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
Mrinal M. Patnaik et al.
BLOOD CANCER JOURNAL (2018)
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia
Mohammad Faizan Zahid et al.
LEUKEMIA & LYMPHOMA (2017)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2017)
Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance
Rangit Vallapureddy et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Human Blood Monocyte Subsets A New Gating Strategy Defined Using Cell Surface Markers Identified by Mass Cytometry
Graham D. Thomas et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML
Akihide Yoshimi et al.
BLOOD (2017)
Monocytosis in polycythemia vera: Clinical and molecular correlates
Daniela Barraco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
Hien Duong Liu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis
Chetasi Talati et al.
BLOOD (2017)
Age-related mutations and chronic myelomonocytic leukemia
C. C. Mason et al.
LEUKEMIA (2016)
Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation
Animesh Pardanani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia
Piyanuch Kongtim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena et al.
BLOOD (2016)
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia
Markus Ball et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Priyanka A. Pophali et al.
CANCER JOURNAL (2016)
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron et al.
CLINICAL CANCER RESEARCH (2016)
Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study
Hidehiro Itonaga et al.
LEUKEMIA RESEARCH (2016)
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Mrinal M. Patnaik et al.
MAYO CLINIC PROCEEDINGS (2016)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
Jane Merlevede et al.
NATURE COMMUNICATIONS (2016)
Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2016)
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2016)
Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
Hien K. Duong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
Dorothee Selimoglu-Buet et al.
BLOOD (2015)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona et al.
BLOOD (2015)
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Argiris Symeonidis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience
Salih Subari et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex
Anand Balasubramani et al.
NATURE COMMUNICATIONS (2015)
ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
J. Perez Botero et al.
BLOOD CANCER JOURNAL (2015)
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome (vol 4, e270, 2015)
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2015)
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
E. Padron et al.
BLOOD CANCER JOURNAL (2015)
A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution
Deniz Peker et al.
ACTA HAEMATOLOGICA (2015)
DNMT3A in haematological malignancies
Liubin Yang et al.
NATURE REVIEWS CANCER (2015)
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution
Guilin Tang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study
Emnet A. Wassie et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review
Mrinal M. Patnaik et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia
M. W. Drummond et al.
LEUKEMIA (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
Lisa Pleyer et al.
LEUKEMIA RESEARCH (2014)
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
What is a promonocyte?
Barbara J. Bain
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Omar Abdel-Wahab et al.
BLOOD (2013)
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Eric Padron et al.
BLOOD (2013)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such et al.
BLOOD (2013)
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia
Koichi Takahashi et al.
BLOOD (2013)
Clonal architecture of chronic myelomonocytic leukemias
Raphael Itzykson et al.
BLOOD (2013)
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Sophie Park et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
John Koreth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
An evolutionary perspective on chronic myelomonocytic leukemia
R. Itzykson et al.
LEUKEMIA (2013)
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
F. Damm et al.
LEUKEMIA (2013)
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
R. R. Laborde et al.
LEUKEMIA (2013)
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
M. M. Patnaik et al.
LEUKEMIA (2013)
Treatment of chronic myelomonocytic leukemia with azacitidine
Eric Wong et al.
LEUKEMIA & LYMPHOMA (2013)
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study
Luana Fianchi et al.
LEUKEMIA & LYMPHOMA (2013)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
Lionel Ades et al.
LEUKEMIA RESEARCH (2013)
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
Mrinal M. Patnaik et al.
BLOOD (2012)
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Manja Meggendorfer et al.
BLOOD (2012)
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Omar Abdel-Wahab et al.
CANCER CELL (2012)
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia
Jumpei Yamazaki et al.
EPIGENETICS (2012)
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
Gandhi Damaj et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review
Michael Thorpe et al.
LEUKEMIA RESEARCH (2012)
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature
Rahel A. Mathew et al.
LEUKEMIA RESEARCH (2012)
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities
Hesham Eissa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
Activity of Azacitidine in Chronic Myelomonocytic Leukemia
Rubens Costa et al.
CANCER (2011)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance
V. Grossmann et al.
LEUKEMIA (2011)
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Nomenclature of monocytes and dendritic cells in blood
Loems Ziegler-Heitbrock et al.
BLOOD (2010)
Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
P. Krishnamurthy et al.
BONE MARROW TRANSPLANTATION (2010)
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
Clara Ricci et al.
CLINICAL CANCER RESEARCH (2010)
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms
Thomas Ernst et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab et al.
BLOOD (2009)
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Long Zhang et al.
BLOOD (2009)
Outcome of allo-SCT for chronic myelomonocytic leukemia
S. Ocheni et al.
BONE MARROW TRANSPLANTATION (2009)
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
Hideki Makishima et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
A. Tefferi et al.
LEUKEMIA (2009)
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation
M-C Kuo et al.
LEUKEMIA (2009)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
Veronique Gelsi-Boyer et al.
BMC CANCER (2008)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
E. J. Feldman et al.
LEUKEMIA (2008)
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
P. W. Wijermans et al.
LEUKEMIA RESEARCH (2008)
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
Oncogenes in myeloproliferative disorders
Ayalew Tefferi et al.
CELL CYCLE (2007)
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
Alfonso Quintas-Cardama et al.
CANCER (2006)
FIP1L1-PDGFRA in eosinophilic disorders:: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature
A. Pardanani et al.
LEUKEMIA RESEARCH (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
M Elliott et al.
BONE MARROW TRANSPLANTATION (2006)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia
P Mittal et al.
BONE MARROW TRANSPLANTATION (2004)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
To the editor: New prognostic parameters for chronic myelomonocytic leukemia?
U Germing et al.
BLOOD (2002)
Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia.: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
F Onida et al.
BLOOD (2002)
Dysplastic versus proliferative CMML -: a retrospective analysis of 91 patients from a single institution
T Nösslinger et al.
LEUKEMIA RESEARCH (2001)
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes
A Venditti et al.
ANNALS OF HEMATOLOGY (2000)
Share Paper
